JP2019503649A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503649A5
JP2019503649A5 JP2018521281A JP2018521281A JP2019503649A5 JP 2019503649 A5 JP2019503649 A5 JP 2019503649A5 JP 2018521281 A JP2018521281 A JP 2018521281A JP 2018521281 A JP2018521281 A JP 2018521281A JP 2019503649 A5 JP2019503649 A5 JP 2019503649A5
Authority
JP
Japan
Prior art keywords
nucleic acid
aav
sequence
acid variant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503649A (ja
JP7088831B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059793 external-priority patent/WO2017075619A1/en
Publication of JP2019503649A publication Critical patent/JP2019503649A/ja
Publication of JP2019503649A5 publication Critical patent/JP2019503649A5/ja
Priority to JP2022093877A priority Critical patent/JP2022137029A/ja
Application granted granted Critical
Publication of JP7088831B2 publication Critical patent/JP7088831B2/ja
Priority to JP2024131729A priority patent/JP2024170416A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521281A 2015-10-30 2016-10-31 核酸変種、アデノ随伴ウイルスベクター及び医薬組成物 Active JP7088831B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022093877A JP2022137029A (ja) 2015-10-30 2022-06-09 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用
JP2024131729A JP2024170416A (ja) 2015-10-30 2024-08-08 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562249001P 2015-10-30 2015-10-30
US62/249,001 2015-10-30
US201662331872P 2016-05-04 2016-05-04
US62/331,872 2016-05-04
US201662349532P 2016-06-13 2016-06-13
US62/349,532 2016-06-13
US201662357874P 2016-07-01 2016-07-01
US62/357,874 2016-07-01
PCT/US2016/059793 WO2017075619A1 (en) 2015-10-30 2016-10-31 Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022093877A Division JP2022137029A (ja) 2015-10-30 2022-06-09 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用

Publications (3)

Publication Number Publication Date
JP2019503649A JP2019503649A (ja) 2019-02-14
JP2019503649A5 true JP2019503649A5 (https=) 2019-12-05
JP7088831B2 JP7088831B2 (ja) 2022-06-21

Family

ID=58630834

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018521281A Active JP7088831B2 (ja) 2015-10-30 2016-10-31 核酸変種、アデノ随伴ウイルスベクター及び医薬組成物
JP2022093877A Pending JP2022137029A (ja) 2015-10-30 2022-06-09 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用
JP2024131729A Pending JP2024170416A (ja) 2015-10-30 2024-08-08 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022093877A Pending JP2022137029A (ja) 2015-10-30 2022-06-09 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用
JP2024131729A Pending JP2024170416A (ja) 2015-10-30 2024-08-08 CpG減少第VIII因子変種、組成物並びに止血障害の処置のための方法及び使用

Country Status (19)

Country Link
US (3) US20180312571A1 (https=)
EP (1) EP3368560B1 (https=)
JP (3) JP7088831B2 (https=)
KR (1) KR20180090795A (https=)
CN (1) CN108368164A (https=)
AU (1) AU2016344030B2 (https=)
BR (1) BR112018008766A2 (https=)
CA (1) CA3002689A1 (https=)
CL (1) CL2018001107A1 (https=)
CO (1) CO2018005306A2 (https=)
IL (1) IL258959B2 (https=)
MX (2) MX2018005490A (https=)
MY (1) MY190926A (https=)
PE (2) PE20231949A1 (https=)
PH (1) PH12018501055A1 (https=)
RU (1) RU2745506C2 (https=)
SA (1) SA518391463B1 (https=)
SG (1) SG11201802972UA (https=)
WO (1) WO2017075619A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
MX390848B (es) 2015-06-23 2025-03-21 Childrens Hospital Philadelphia Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
PE20200722A1 (es) * 2017-08-01 2020-07-21 Spark Therapeutics Inc Metodos de terapia genica del factor viii (fviii)
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
KR101952102B1 (ko) * 2017-12-07 2019-02-26 주식회사 지앤피바이오사이언스 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
TW202016298A (zh) 2018-05-14 2020-05-01 美商拜奧馬林製藥公司 Aav 載體於幼年受試者中之穩定表現
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
BR112021003399A2 (pt) * 2018-08-24 2021-05-18 Spark Therapeutics, Inc. sequências de promotores otimizadas, construtos de expressão livres de íntron e métodos de uso
CA3119349A1 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
SG11202109850SA (en) 2019-03-13 2021-10-28 Generation Bio Co Non-viral dna vectors and uses thereof for expressing fviii therapeutics
CN114929735A (zh) * 2019-11-01 2022-08-19 自由行疗法有限公司 因子viii构建体
JP2023510392A (ja) * 2020-01-16 2023-03-13 武田薬品工業株式会社 フェニルケトン尿症に対するアデノ随伴ウイルスベースの遺伝子治療
GB202009039D0 (en) 2020-06-15 2020-07-29 Univ Bristol Therapy
WO2023036054A2 (en) * 2021-09-08 2023-03-16 Inspirar Limited Composition and method for treating hemophilia
KR20250007615A (ko) * 2022-04-28 2025-01-14 조인트 스탁 컴퍼니 "바이오케드" Fviii-bdd를 인코딩하는 코돈 최적화된 핵산
JP2025529195A (ja) * 2022-08-31 2025-09-04 ハイドロジーン セラピューティクス,インコーポレイテッド 流体力学的遺伝子送達のための方法および組成物
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性/高分泌発現型の第viii因子改変体、高発現型の第viii因子コード核酸及びそれらの用途
WO2025180508A1 (en) * 2024-02-29 2025-09-04 Shanghai Vitalgen Biopharma Co., Ltd. Human factor viii variant expression cassettes and uses thereof for treating hemophilia a

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1240900B1 (en) * 1999-12-24 2009-05-06 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Factor viii or von willebrand factor for the treatment of hemorrhagic diseases associating thrombopathy
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
EP2822577B1 (en) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
NZ701693A (en) 2012-04-18 2017-02-24 The Children’S Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
US20140271550A1 (en) 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
IL297919A (en) 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3044231B1 (en) 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii
WO2015054439A2 (en) * 2013-10-08 2015-04-16 Haplomics, Inc. Hybrid factor viii polypeptides for use to treat hemophilia a
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
CN107427557B (zh) * 2014-08-13 2022-01-04 费城儿童医院 用于包装和表达变体因子viii以治疗血友病的改良表达组件
MY189674A (en) 2015-10-28 2022-02-24 Sangamo Therapeutics Inc Liver-specific constructs, factor viii expression cassettes and methods of use thereof
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
PE20200722A1 (es) 2017-08-01 2020-07-21 Spark Therapeutics Inc Metodos de terapia genica del factor viii (fviii)

Similar Documents

Publication Publication Date Title
JP2019503649A5 (https=)
JP2021087431A5 (https=)
JP2021003120A5 (https=)
JP2021106619A5 (https=)
JP2021118724A5 (https=)
JP2020533276A5 (https=)
JP2024009857A5 (https=)
JP2020522269A5 (https=)
IL273261B2 (en) Adeno-associated virus variant capsids and methods of using them
JP2019116492A5 (https=)
JP2018506261A5 (https=)
JP2018522529A5 (https=)
JP2022529631A5 (https=)
JP2020513811A5 (https=)
JP2022547197A5 (https=)
RU2018119710A (ru) Кодирующие фактор viii варианты с пониженным содержанием cpg, композиции и способы, и применение в лечении нарушений гемостаза
JP2021512072A5 (https=)
JP2017509632A5 (https=)
JP2018531609A5 (https=)
JP2021523718A5 (https=)
JP2017529395A5 (https=)
JP2022524434A5 (https=)
JP2022525302A5 (https=)
JP2023524414A5 (https=)
JP2023520764A5 (https=)